Abstract We present a case of recurrent proliferative glomerulonephritis with monoclonal immunoglobulin G (IgG) deposits (PGNMID) that progressed rapidly to allograft failure. A 56-year-old man had progressed to endstage renal failure within 1 year after the diagnosis of membranoproliferative glomerulonephritis (MPGN) by kidney biopsy. He underwent living donor kidney transplantation from his brother 6 months later. Serial allograft biopsies revealed early glomerular deposition of IgG, C1q, and C3 at post-operative day 26, and gradual progression of the glomerular deposition and histology of glomerulonephritis. Several immunosuppressive therapies did not prevent proteinuria, microhematuria, and graft dysfunction, and the patient returned to hemodialysis at 7 months after transplantation. Retrospectively, we demonstrated monoclonal IgG3j deposition in the native and allograft kidney, and the patient was diagnosed with recurrent PGNMID. The serial graft biopsies revealed the pathological details of the progression of PGNMID. This is a rare case of PGN-MID that recurred and progressed rapidly to graft failure after kidney transplantation.
light-chain deposition disease (LCDD), light-and heavychain deposition disease (LHCDD), type 1 cryoglobulinemic glomerulonephritis, immunotactoid glomerulonephropathy (IT), and fibrillary glomerulonephritis (FGN). The deposits are negative for Congo red staining and usually show a granular texture without substructures, as observed in IT or FGN localized to glomeruli [1, 2] .
Although most patients have no detectable monoclonal IgG (M-peak) in their serum or urine, the glomerular deposits of PGNMID are thought to be derived from circulating monoclonal IgG. Thus, PGNMID in kidney allografts can recur frequently [4] [5] [6] , although its recurrence rate is uncertain due to its rarity. The recurrence of PGN-MID is usually detected at 3-5 months after transplantation using episode biopsies [4] [5] [6] , whereas the timing of recurrence of MPGN varies from 1 week to several years after transplantation [7] [8] [9] . The renal prognosis is usually favorable, with the exception of cases with concurrent infection [5] . Here, we report a rare case of PGNMID that recurred on post-operative day (POD) 26 and progressed to graft failure within 7 months after kidney transplantation. The serial graft biopsies revealed the pathological details of the progression of PGNMID.
Case report
A 56-year-old man with nephrotic syndrome was diagnosed with MPGN by kidney biopsy in December 1993 (Fig. 1) . He had no monoclonal IgG (M-peak) in his serum or urine. There was no evidence of cryoglobulinemia, hepatitis virus infection, or any other cause of secondary MPGN from his laboratory data (Table 2) . Oral prednisolone (1 mg per kg body weight) therapy combined with renin-angiotensin system (RAS) blockade and antiplatelet drugs, followed by cyclophosphamide (50 mg per day), was administered. However, microhematuria (20-100/ high-power field), proteinuria (2.5-9.2 g per day), and hypocomplementemia (C3 0.34-0.48 g/L; C4 0.11-0.17 g/ L; CH50 27-48 kU/L) persisted, and his renal function deteriorated gradually. He started hemodialysis (HD) therapy 1 year after the diagnosis, in November 1994 (Fig. 2a) . Six months later, he received a living donor kidney transplant [ABO compatible and two human leukocyte antigen (HLA) mismatches] from his 56-year-old brother in June 1995 (Fig. 2a) . The initial immunosuppressive therapy comprised cyclosporine (CYA), methylprednisolone, and mycophenolate mofetil (MMF). Cyclosporine was started at 6 mg per kg body weight and was adjusted to maintain a trough level in whole blood of 2-3 9 10 -4 g/L. MMF was started and maintained at 2 g per day according to the number of white blood cells. The clinical course after transplantation was unremarkable, and he was discharged from the hospital with a serum creatinine (sCr) level of 132.6 lmol/L. At his first visit to the outpatient clinic, a slight elevation of the sCr level (167.9 lmol/L) and microhematuria without proteinuria were detected, and an allograft biopsy was performed on POD 26, which revealed no significant tubulointerstitial or vascular rejection without significant glomerular morphology. However, by immunofluorescence analysis, slight mesangial deposition of IgG, C3, and C1q was detected, suggesting the possibility of early recurrence of MPGN. Intravenous steroid pulse therapy (0.5 g per day for 2 days) and subsequent muromonab-CD3 (Orthoclone OKT3 Ò ) were administered for the treatment of presumed vascular rejection. Subsequently, his sCr temporally declined to 123.76 lmol/L; however, microhematuria persisted. During the subsequent 3 weeks, his sCr level gradually elevated to 185.6 lmol/L, and allograft biopsy was performed on POD 57. Histological analysis showed similar minimal tubulointerstitial lesions with no sign of vascular rejection. Next, the other episodes of sCr elevation occurred on PODs 74 and 90. Because of the persistent increase in the sCr (Fig. 2b) . In addition to microhematuria, proteinuria (0.2-0.4 g per day) was detected after POD 90 and became markedly high (3.6 g per day) in October 1995. Thus, we added azathioprine (0.1 g per day); however, his sCr level finally reached the level of end-stage renal disease (ESRD), and HD was restarted in December 1995 (Fig. 2a) . Because the concept of PGNMID had not been established when the patient was treated in the 1990s, he was diagnosed with MPGN. After establishment of the PGNMID concept, we retrospectively confirmed the monoclonality of glomerular IgG deposits using immunofluorescence analyses for IgG subclasses, as well as the j and k light chains, and recognized that glomerular IgG was composed of monoclonal IgG3j in both the native kidney biopsy (Fig. 1 ) and allograft kidney biopsies (Fig. 2b) . Therefore, we concluded that his original kidney disease was PGNMID (IgG3j type), which recurred in the kidney allograft. By electron microscopy, a small amount of EDDs was first detected in the mesangium in the allograft biopsy on POD 26, and these EDDs were more clearly detected on POD 57 (Fig. 3a) . In the subsequent allograft biopsy on POD 90, deposits were observed in both mesangial and subendothelial areas accompanying mesangial interposition (Fig. 3b) . Endocapillary proliferation with inflammatory cells was found on POD 164 (Fig. 3c) . Under high magnification, the deposits had a granular texture without organized microstructures such as microtubules or fibrils (Fig. 3d) . After obtaining informed consent from the patient, we evaluated his serum IgG subclass content: total IgG 
Discussion
Here, we present a case of PGNMID that rapidly progressed to renal failure in both the native and allograft kidney. The original diagnosis was MPGN; however, we retrospectively diagnosed the present case with PGNMID by IgG heavy-chain subclass and light-chain analysis of the glomerular deposits. Recurrent glomerular diseases usually develop within the first 2 years after allograft transplantation [11] . Seven cases of recurrent PGNMID have been reported to date; these were histologically diagnosed 3-22 months after transplantation [3] [4] [5] . In the present case, monoclonal IgG and complement deposition were Half a year later, he was transplanted the allograft kidney from his brother. PGNMID recurred within at least post-operative day (POD) 26 and his renal graft failure after 7 months in spite of several immunosuppressive therapies. The vertical bi-axis shows serum Cr (red) and urinary protein (yellow) levels.Biopsy (green arrow), HD hemodialysis (red arrow), Tx transplantation, PSL prednisolone, CPA cyclophosphamide, CYA cyclosporine, MP methylprednisolone, MMF mycophenolate mofetil, OKT3 muromonab-CD3, DSG 15-deoxyspergualin, AZ azathioprine. b Glomerular morphology showed minor abnormalities at transplantation (0 h) and POD 26, mild mesangial proliferative at POD 76, and membranoproliferative at PODs 164 and 215. IgG3 deposition appeared at POD 26 when glomerular changes were minimal and concomitantly progressed from the mesangial pattern (POD76) to mesangial and capillary patterns (PODs 164 and 215) detected at POD 26, which is the earliest case among the previous cases.
The clinical outcomes of PGNMID are various, and Nasr et al. [2] reported that 7/32 (21.9 %) patients with PGNMID progressed to renal failure. The authors suggested that the favorable outcome was attributable to disease stabilization by early immunosuppressive therapy that included a regimen of high-dose prednisolone and rituximab [4] . However, Masai et al. [12] reported a patient with PGNMID (IgG3j type) who showed resistance to steroids and cytotoxic agents, and progressed to kidney failure. These reports and our case indicate that the outcome of PGNMID is not always favorable. Especially in the recurrent cases, sufficient immunosuppressive therapy, such as high-dose prednisolone combined with rituximab or plus cyclophosphamide, should be selected for the treatment of PGNMID according to recent recommendations [4] .
The most common type of deposit in unfavorable cases of primary and recurrent PGNMID remains unclear due to the small numbers of patients in previous studies [4] [5] [6] . Nasr et al. [2] reported that the most common subtype of primary PGNMID was IgG3j (53.1 %), followed by IgG1j (21.9 %). In the recurrent cases with PGNMID, the IgG subtypes was IgG3j in five cases and IgG3k and IgG2k in one case, respectively [4] [5] [6] . The IgG3 subtype possesses the following unique physicochemical properties: self-aggregation via Fc-Fc interactions, the highest molecular weight, the greatest complement-fixing ability, and the most positive charge, making this subtype intrinsically ''nephritogenic'' [13, 14] .
On the other hand, Debiec et al. [15] reported a patient with recurrent membranous nephropathy 13 days after kidney transplantation whose graft biopsy specimen showed granular staining monoclonal IgG3j and corresponding PLA2R antigen expressed on donor podocytes. Treatment with rituximab stabilized both proteinuria and serum creatinine, and circulating anti-PLA2R became undetectable. This case also suggested that a presence of circulating monoclonal immunoglobulin, especially the IgG3 subclass, could deposit in the allograft soon after the transplantation and cause the recurrent glomerular disease through complement activation. Further research is Fig. 3 Electron microscopic findings in the allograft kidney. Electron-dense deposits (EDDs) were found in the mesangial area at POD 57 (a), and in both the mesangial and subendothelial areas accompanying mesangial interposition at POD 90 (b) (93,000).
Endocapillary proliferation with inflammatory cells was found at POD 164 (93000). Under high magnification, the deposits displayed a granular texture without organized microstructures such as microtubules or fibrils (915000) (d) required to clarify the pathogenesis and progression of PGNMID in relation to the IgG subclass.
The glomerular morphology of PGNMID is various: membranoproliferative (56.8 %), endocapillary proliferative (35.1 %), mesangioproliferative (2.7 %), membranous (5.4 %), and crescentic (32.4 %) [2] . Moreover, the locations of EDDs are also various: mesangial (94.6 %), subendothelial (100 %), subepithelial (56.8), and intramembranous (13.5 %) [2] . In the present case, light microscopic glomerular change was minimal at PODs 26 and 57, mesangial proliferation and intracapillary macrophage infiltration were subsequently evident at POD 76, and capillary involvement of glomerular inflammation (membranoproliferative lesion) became apparent at PODs 94, 164, and 215. EDDs were first detected in the mesangial region (at POD 26), and subsequently appeared in the subendothelial region (POD 57 and later). The morphological transition of the present case, therefore, indicates that the various glomerular morphologies of PGNMID may be influenced by the stage of the disease progression.
In conclusion, we retrospectively diagnosed and evaluated a case of recurrent PGNMID that progressed rapidly to allograft failure. Sufficient immunosuppressive therapy, such as high-dose prednisolone combined with rituximab or plus cyclophosphamide, is recommended for the treatment of PGNMID in general, but our case indicated that the outcome of PGNMID in the kidney allograft is not always favorable.
